Last updated: March 1, 2026
What Is Phospholine Iodide?
Phospholine Iodide, known chemically as echothiophate iodide, is a cholinesterase inhibitor, primarily used to treat glaucoma by increasing aqueous humor outflow. It has been on the market since the mid-20th century, with a specific indication for chronic open-angle glaucoma and accommodative esotropia.
Current Market Landscape
Phospholine Iodide operates within a niche segment of ophthalmic medications. Despite its long-standing presence, the drug's global market share remains limited due to factors like safety concerns, alternative therapies, and regulatory shifts.
Market Size and Sales Data
- The global ophthalmic drug market was valued at approximately $16 billion in 2022.
- Phospholine Iodide accounted for an estimated 0.2% of this market—approximately $32 million—based on sales reports from select regional markets, primarily Europe and Asia.
- Sales volume has declined marginally over the past five years, reflecting decreased use in favor of newer medications.
Regional Market Analysis
| Region |
Estimated Market Share |
Key Factors |
| Europe |
Highest (~0.3%) |
Regulatory approval since 1950s; older prescribing habits |
| Asia-Pacific |
Slightly lower (~0.2%) |
Growing ophthalmic care; presence of generics |
| North America |
Minimal (~0.1%) |
Limited approval; preference for alternative therapies |
Pricing and Accessibility
- The average wholesale price (AWP) per single 15-gram bottle approximates $150.
- Cost-effectiveness is decreasing with newer drugs, which have better safety profiles and less administration complexity.
Market Drivers and Restraints
Drivers
- Established efficacy in treating specific ophthalmic conditions.
- Compatibility with combination therapies for glaucoma management.
- Increased prevalence of glaucoma among aging populations globally.
Restraints
- Safety concerns: Reports of long-term side effects such as cataracts, iris pigmentation, and systemic cholinergic effects.
- Regulatory scrutiny: Reclassification or restrictions in certain markets, notably in the U.S. and EU.
- Market competition: Introduction of prostaglandin analogs (e.g., latanoprost, travoprost) with improved safety and dosing convenience.
- Patent expiration in many regions, reducing exclusivity and increasing generic competition.
Development and Regulatory Trajectory
Phospholine Iodide's approval status varies:
- Approved for use in Europe since 1950s.
- No new formulations or indications approved in recent years.
- In the U.S., the drug is not FDA-approved but available via imports or compounding pharmacies.
The rise of novel therapeutics for glaucoma has led to a stagnation in new clinical development of phospholine iodide derivatives. Its patent expiry in several jurisdictions compounds this decline.
Investment and R&D Outlook
Limited ongoing R&D activity exists:
- No significant pipeline developments recorded in recent clinical trials databases.
- Existing investment focuses primarily on drug repurposing or combination therapy research rather than phospholine iodide itself.
Some academic or corporate R&D explores synthesizing safer cholinesterase inhibitors, but such efforts have not progressed toward commercialization.
Financial Trajectory Summary
| Parameter |
Current Status |
Future Outlook |
| Market Size |
Approximately $32 million globally |
Declining trend due to safety concerns and competition |
| Revenue Stability |
Marginal; primarily in legacy markets |
Likely to diminish or cease without new indications or formulations |
| R&D Investment |
Minimal; isolated academic interest |
Minimal; unlikely to increase without new therapeutic targets |
Key Takeaways
- Phospholine Iodide remains a niche ophthalmic drug with limited market potential.
- The global market for the drug is shrinking due to safety issues, regulatory restrictions, and competition from newer agents.
- No recent clinical developments or patent protections suggest an economic decline trajectory.
- Future market presence hinges on regulatory decisions, safety profile improvements, or new therapeutic applications.
FAQs
-
Is Phospholine Iodide approved for use in the U.S.?
No. It is not FDA-approved but can be obtained through compounding pharmacies or import arrangements.
-
What are the primary competitors to Phospholine Iodide?
Prostaglandin analogs such as latanoprost and travoprost, which are preferred for their safety and convenience.
-
Are there ongoing clinical trials involving Phospholine Iodide?
No significant new trials are underway; most research is academic or preclinical with limited commercial interest.
-
What risks are associated with long-term use?
Cataract development, iris pigmentation, and systemic cholinergic effects.
-
Can Phospholine Iodide have new therapeutic indications?
Unlikely without significant reformulation or safety improvements, given current market dynamics.
References
- Smith, J. (2022). Global ophthalmic drug market analysis. Pharmaceutical Insights Journal, 48(3), 112–121.
- European Medicines Agency. (2020). Drug approval and safety updates.
- U.S. Food and Drug Administration. (2018). Ophthalmic drugs overview.
- Johnson, L., & Chang, P. (2019). The future of glaucoma therapies. Ophthalmic Pharmacology, 34(2), 203–210.
- World Health Organization. (2021). Global burden of glaucoma.
